相关实验视频

Updated: Sep 12, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

对肝细胞癌的同时综合增强和保护质子束疗法方法

Kanokphorn Thonglert^1,2, Matthew D Greer³, Stephanie K Schaub^1,4

¹Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.

Clinical and translational radiation oncology

|August 8, 2025

概括

与质子束疗法 (SIB-PBT) 同时整合增强和保护是肝细胞癌 (HCC) 的安全有效治疗方法,可使剂量升级,同时保护有风险的器官 (OAR). 这种方法证明了HCC患者有希望的局部控制和生存率.

科学领域:

辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

与质子束疗法 (SIB-PBT) 同时的综合增强和保护提供了在瘤中剂量升级的潜力,同时节省了有风险的器官 (OAR).
肝细胞癌 (HCC) 中SIB-PBT的临床结果需要进一步评估.

研究的目的:

评估SIB-PBT在被诊断为HCC的患者的安全性和有效性.
评估SIB-PBT在遵守OAR剂量限制的同时升级瘤剂量的能力.

主要方法:

在2014年至2021年期间,对47名接受SIB-PBT治疗的HCC患者进行了回顾性审查.
辐射剂量从36-67.5 Gy (RBE) 分为15个分量,SIB-PBT用于最大限度地减少OAR暴露,在不同的剂量水平治疗目标,或两者兼而有之.
使用卡普兰-梅尔,细灰累积发病率和描述性统计数据分析了生存率,局部控制和毒性.

主要成果:

大多数瘤 (87%) 位于胃肠道 (GI) 光线OARs的2厘米范围内.
瘤中位直径为9.2厘米. 大多数患者 (91%) 接受了<45 Gy (RBE) 到0.5 毫升的GI OARs.
在22个月的随访中位数,两年局部衰竭为12%,两年无进展生存率为12%,整体生存率为49%. 一名患者出现3级急性恶心/吐;没有观察到严重的胃肠道毒性.

结论:

SIB-PBT促进了OAR保护和异质瘤剂量升级.
该技术被证明是HCC的安全有效治疗方式.

关键词:

肝细胞癌 (HCC) 是一种肝细胞癌.强度调节质子疗法 (IMPT) 是一种强度调节质子疗法.质子束疗法 (PBT) 是一种治疗方法.辐射疗法辐射疗法同时集成提升/保护 (SIB/SIP)

更多相关视频

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...